Literature DB >> 15638274

The effect of varying dietary starch and fat content on serum creatine kinase activity and substrate availability in equine polysaccharide storage myopathy.

W P Ribeiro1, S J Valberg, J D Pagan, B Essen Gustavsson.   

Abstract

The effect of dietary starch and fat content on serum creatine kinase (CK) activity and substrate availability was evaluated in 4 mares of Quarter Horse-related breeds with polysaccharide storage myopathy (PSSM). Four isocaloric diets ranging in digestible energy (DE) from 21.2% (diet A), 14.8% (B), 8.4% (C), to 3.9% (D) for starch, and 7.2% DE (diet A), 9.9% (B), to 12.7% DE (diet C and D) for fat were fed for 6-week periods (4 weeks with exercise) using a 4 X 4 Latin square design. Postprandial glucose and insulin responses were measured, and 4 hours postexercise, serum CK activity, glucose, insulin, free fatty acids (FFA), and beta-hydroxybutyrate (beta-HBA) were analyzed. Glycogen, glucose-6-phosphate, citrate synthase, 3-hydroxy-acyl-CoA dehydrogenase, lactate dehydrogenase as well as abnormal polysaccharide and lipid content were measured in middle gluteal muscle samples. Postprandial insulin and glucose response was higher for diet A versus D. Log CK activity was higher with diets A, B, and C versus D. Daily insulin was higher and FFA lower on diet A versus B, C, and D, whereas glucose varied only slightly with diet. Muscle oxidative capacity and lipid stores were low in PSSM horses and muscle glycogen and abnormal polysaccharide content high on both diets A and D. Individual variation occurred in the response of PSSM horses to diets differing in starch and fat content. However, for those horses with clinical manifestations of PSSM, a diet with <5% DE starch and >12% DE fat can reduce exertional rhabdomyolysis, potentially by increasing availability of FFA for muscle metabolism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15638274     DOI: 10.1892/0891-6640(2004)18<887:teovds>2.0.co;2

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  8 in total

Review 1.  Equine clinical genomics: A clinician's primer.

Authors:  M M Brosnahan; S A Brooks; D F Antczak
Journal:  Equine Vet J       Date:  2010-10       Impact factor: 2.888

2.  Glycogen synthase (GYS1) mutation causes a novel skeletal muscle glycogenosis.

Authors:  Molly E McCue; Stephanie J Valberg; Michael B Miller; Claire Wade; Salvatore DiMauro; Hasan O Akman; James R Mickelson
Journal:  Genomics       Date:  2008-03-20       Impact factor: 5.736

3.  Suspected myofibrillar myopathy in Arabian horses with a history of exertional rhabdomyolysis.

Authors:  S J Valberg; E C McKenzie; L V Eyrich; J Shivers; N E Barnes; C J Finno
Journal:  Equine Vet J       Date:  2015-09-07       Impact factor: 2.888

4.  251st ENMC international workshop: Polyglucosan storage myopathies 13-15 December 2019, Hoofddorp, the Netherlands.

Authors:  Pascal Laforêt; Anders Oldfors; Edoardo Malfatti; John Vissing
Journal:  Neuromuscul Disord       Date:  2021-01-23       Impact factor: 4.296

5.  Physiological response to a breed evaluation field test in Icelandic horses.

Authors:  G J Stefánsdóttir; S Ragnarsson; V Gunnarsson; A Jansson
Journal:  Animal       Date:  2014-01-06       Impact factor: 3.240

6.  Pre-race and race management impacts serum muscle enzyme activity in Australian endurance horses.

Authors:  Petra Buckley; David J Buckley; Rafael Freire; Kristopher J Hughes
Journal:  Equine Vet J       Date:  2021-11-08       Impact factor: 2.692

7.  Effects of dietary energy sources on early postmortem muscle metabolism of finishing pigs.

Authors:  Yanjiao Li; Changning Yu; Jiaolong Li; Lin Zhang; Feng Gao; Guanghong Zhou
Journal:  Asian-Australas J Anim Sci       Date:  2017-06-26       Impact factor: 2.509

8.  Muscle glycogen concentrations and response to diet and exercise regimes in Warmblood horses with type 2 Polysaccharide Storage Myopathy.

Authors:  Zoë J Williams; Megan Bertels; Stephanie J Valberg
Journal:  PLoS One       Date:  2018-09-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.